Navigation Links
Big Lottery to fund scientific research
Date:11/5/2008

Scientists at the University of Liverpool have received 500,000 to develop a treatment for the rare, genetic disease Alkaptonuria.

Patients being treated for the disorder do not have enough of the enzyme, homogentisic acid oxidase, which causes acid to build up in the body. Some of this acid is eliminated in the urine, but the remainder is deposited in body tissue where it is toxic. The result is ochronosis; the formation of a black pigment which binds to bone, cartilage, and skin.

The research at Liverpool will be funded by the Alkaptonuria (AKU) Society following the organisation's successful bid to the Big Lottery Fund. The research will use models of ochronosis that have been developed at the University. Tissue samples donated by Alkaptonuria patients undergoing joint replacement surgery will also be analysed.

There is no known cure for the disease which affects one in 200,000 people worldwide and can leave sufferers with crippling osteoarthritis in their spine and large joints, heart disease and in need of joint replacement surgery.

Head of Human Anatomy and Cell Biology, Professor Jim Gallagher, said: "The black pigment that leaks into the bloodstream and attaches itself to joint cartilage is the main cause of illness. What is interesting is that the pigment only attaches itself to certain areas of cartilage, whilst other sections remain pigment-free.

"If we can find out why it does this we could prevent the pigment from binding altogether. This would dramatically reduce the risk of arthritis in the joints of Alkaptonuria sufferers. Only by understanding the basic mechanisms of the development of ochronosis will we be able to develop strategies to prevent it."

Scientists will use their ochronosis models to provide a fundamental understanding of the development of the condition and to develop potential therapies.


'/>"/>

Contact: Laura Johnson
laura.johnson@liv.ac.uk
44-01-517-942-026
University of Liverpool
Source:Eurekalert

Page: 1

Related medicine news :

1. New Lottery Ticket Envisions a World Free of MS
2. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
3. Thomson Scientific Predicts Nobel Laureates
4. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
5. Thomson Scientific Announces BONDplus for Biological Researchers
6. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
7. International Society of Hair Restoration Surgery Hosts 15th Annual Scientific Meeting in Las Vegas, September 26-30, 2007
8. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
9. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
10. Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research
11. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: